“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

Immunovia and
IMMray™ technology
(10 min)

Financial reports

February 2019

Immunovia AB published the company’s Full Year Report 2018 on Thursday, February 14, 2019, at 5:05 p.m. CET.

Financial reports


5 March, 2019
Carnegie Healthcare Seminar 2019
Place: Stockholm, Sweden
11-13 March, 2019
9th Alpbach Workshop on Affinity Proteomics
Place: Alpbach, Austria
14 March, 2019
Annual summit PCUK: Accelerating Success
Place: London, UK
All events

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports